comparemela.com

Latest Breaking News On - Antonio breast cancer - Page 24 : comparemela.com

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer PFS follows. | December 8, 2022

United statesSan antonioMartin lehrGina cestariCompany nasdaqContext therapeutics incExchange commissionWisconsin oncology networkMenarini groupSan antonio breast cancerAntonio breast cancerPrivate securities litigation reform actContext therapeutics inc stock exchangePress releaseFs us21077p1084

Concerns Around Sex, Fertility Often Ignored in Breast Cancer Care: Survey

TUESDAY, Dec. 6, 2022 (HealthDay News) Shehzin Tietjen was 27 years old when she felt a lump in one of her breasts while in the shower.

United statesSan antonioDana farber cancer instituteAhlum hansonHarold bursteinShehzin tietjenHealthday newsLiving beyond breast cancerArin ahlum hansonAntonio breast cancerConsumer news

Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022

/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that new data presentations.

San antonioUnited statesUnited kingdomJosepha sparanoGisela pedrozaRick baehnerFederico maiardiMegan jonesSciences corpSciences on facebookNational cancer instituteSciences on twitter exactsciencesCancer research groupExchange commissionGenomic health incSciences precision oncology portfolio

AstraZeneca Reports Positive Survival In Phase 3 Trial Of ENHERTU In HER2 Metastatic Breast Cancer

LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) Wednesday announced that ENHERTU, a HER2-directed antibody-drug conjugate or ADC, achieved statistically significant overall survival, reducing the risk

San antonioUnited statesCity ofUnited kingdomTrastuzumab emtansineDaiichi sankyoAntonio breast cancer

EXACT SCIENCES CORP: Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS 2022

New independent clinical evidence from the pivotal TAILORx and RxPONDER trials support the role of the Oncotype DX Breast Recurrence Score test, the only genomic test to predict chemotherapy

San antonioUnited statesUnited kingdomJosepha sparanoGisela pedrozaRick baehnerFederico maiardiMegan jonesSciences corpSciences on facebookNational cancer instituteSciences on twitter exactsciencesCancer research groupExchange commissionPrnewswire exact sciences corpGenomic health inc

vimarsana © 2020. All Rights Reserved.